CoChat

Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies

Bertotti, Andrea, Sassi, Francesco · 2015 · Clinical Cancer Research

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Abstract

Monoclonal antibodies targeting the EGF receptor (EGFR) tyrosine kinase, such as cetuximab and panitumumab, achieve clinically meaningful responses in patients affected by head and neck and colorectal cancers. Despite this evidence of efficacy, no genomic abnormalities that robustly predict sensitivity to EGFR blockade have been yet identified. This suggests that, in some tumor contexts, EGFR dependency is not acquired during neoplastic transformation and rather reflects an aberrant declination of physiologic traits typical of normal tissue counterparts. Indeed, EGFR signals are crucial for the reconstitution of damaged mucosa in the context of acute inflammation, and their sustained activation is likely to turn into a pro-oncogenic cue during chronic inflammation. Although positive predictors of response to anti-EGFR antibodies remain unknown, multiple determinants of resistance have been described, including alterations interfering with antibody–receptor interaction, deregulation of parallel signaling pathways, and mutations in downstream transducers. These findings provide new opportunities for the optimization of therapeutic strategies based on drug combinations. However, the emerging notion that genetic interactions and compensatory mechanisms may affect—both positively and negatively—the efficacy of targeted therapies complicates the rational design of combinatorial approaches and implies a rethinking of the criteria required to prioritize laboratory findings for clinical validation in investigational trials. Clin Cancer Res; 21(15); 3377–83. ©2015 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-0848

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 62 references

Cited by

See all 45

Metadata

Authors
Bertotti, A., & Sassi, F.
Affiliations
  • Istituto Nazionale Biostrutture e Biosistemi (IT)
  • Candiolo Cancer Institute (IT)
Venue
Clinical Cancer Research
Published
2015-08-01
Volume
21
Issue
15
Pages
3377-3383
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W1919718700
Cited by
45
References
63
Citations by year
2026: 2 · 2025: 1 · 2024: 5 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 6 · 2019: 6 · 2018: 4 · 2017: 2 · 2016: 7 · 2015: 2
FWCI
2.18
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
EGFR, anti-EGFR monoclonal antibody, cetuximab, panitumumab, drug resistance, predictive biomarkers, head and neck cancer, colorectal cancer, chronic inflammation, compensatory signaling pathways, combination therapy, targeted therapy
MeSH terms
Antibodies, Anti-Idiotypic, Head and Neck Neoplasms, Humans, Colorectal Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0848
The paper
Bertotti, A., & Sassi, F. (2015). Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0848

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.